PMID- 21605146
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20240323
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 34
IP  - 2
DP  - 2011 Jul
TI  - The combination of sorafenib with transarterial chemoembolisation for 
      hepatocellular carcinoma.
PG  - 205-13
LID - 10.1111/j.1365-2036.2011.04697.x [doi]
AB  - BACKGROUND: Standard of practice involves using transarterial therapy for 
      multifocal hepatocellular carcinoma (HCC) alone and sorafenib only for more 
      advanced HCC, but the sorafenib and transarterial therapy combination may provide 
      greater efficacy. AIM: To evaluate the safety and efficacy of concurrent 
      sorafenib and transarterial therapy in HCC. METHODS: Consecutive cases of HCC 
      were treated with sorafenib and transarterial therapy, receiving sorafenib 2 to 
      4weeks before transarterial therapy. Baseline clinical parameters, adverse events 
      (AEs) and survival were collected. RESULTS: A total of 47 patients received 
      sorafenib and transarterial therapy. The majority of the patients were male (70%) 
      with HCV (60%), median age of 60years, good performance status (0-1), stable 
      cirrhosis (Child: A 72%; B 28%), unresectable tumour (stage: B 81%; C 19%) and 
      median AFP of 24ng/mL. Median follow-up was 12months and median time on sorafenib 
      was 6months. LC Bead TACE was used with a median frequency of 3. The majority of 
      the patients (89%) experienced AEs. The most common AEs were fatigue (51%), 
      hand-foot skin reaction (51%) and diarrhoea (43%). Grade 3 and 4 AEs included 
      fatigue (13%) and hand-foot skin reaction (26%). Most patients required a dose 
      reduction (66%). The main AE related to transarterial therapy was post-TACE 
      syndrome (23%). The disease control rate was 68% at 6months. Overall median 
      survival rate was 18.5months (95% CI 16.1-20.9months). CONCLUSION: Concurrent 
      sorafenib and transarterial therapy is overall safe with no unexpected side 
      effects and encouraging efficacy that warrants further study.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Cabrera, R
AU  - Cabrera R
AD  - Division of Gastroenterology, Hepatology and Nutrition, Section of Hepatobiliary 
      Diseases, Department of Medicine, University of Florida, Gainesville, FL 
      32610-0214, USA. cabrer@medicine.ufl.edu
FAU - Pannu, D S
AU  - Pannu DS
FAU - Caridi, J
AU  - Caridi J
FAU - Firpi, R J
AU  - Firpi RJ
FAU - Soldevila-Pico, C
AU  - Soldevila-Pico C
FAU - Morelli, G
AU  - Morelli G
FAU - Clark, V
AU  - Clark V
FAU - Suman, A
AU  - Suman A
FAU - George, T J Jr
AU  - George TJ Jr
FAU - Nelson, D R
AU  - Nelson DR
LA  - eng
GR  - K24 CA139570/CA/NCI NIH HHS/United States
GR  - KL2 RR029888/RR/NCRR NIH HHS/United States
GR  - KL2RR029888/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110523
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Benzenesulfonates/adverse effects/*therapeutic use
MH  - Carcinoma, Hepatocellular/drug therapy/*therapy
MH  - *Chemoembolization, Therapeutic
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/drug therapy/*therapy
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Sorafenib
MH  - Treatment Outcome
PMC - PMC3807574
MID - NIHMS384209
EDAT- 2011/05/25 06:00
MHDA- 2011/12/13 00:00
PMCR- 2013/10/25
CRDT- 2011/05/25 06:00
PHST- 2011/05/25 06:00 [entrez]
PHST- 2011/05/25 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2013/10/25 00:00 [pmc-release]
AID - 10.1111/j.1365-2036.2011.04697.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 
      10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.